Blog

Latest news about encapsia

Card image cap
Innovative technology for clinical trials is now, more than ever, necessary to deliver decentralized trials (DCT) and enable design of hybrid protocols that support trial continuity and patient-centricity. We’ve added new capabilities for encapsia, after we’ve seen increased demand for its use in decentralized trials. Encapsia delivers a complete solution to gather and manage multiple live clinical data sources and apply real-time data management, sophisticated visualizations, analytics, and AI. Encapsia was designed to address the pain around remote collection, integration, and availability of disparate data.
Card image cap
Decentralized trials are defined by the FDA as the decentralization of clinical trial operations where technology is used to communicate with study participants and collect data. These trials can be fully DCT (the study participant can participate in the entire clinical trial from their home or other convenient location) or hybrid DCT (combine the use of both sites and remote locations and is currently the most common type of DCT being implemented).
Card image cap
We are excited to announce that Cmed has today joined the AIXIAL Group and ALTEN Group. ALTEN is a world leader in Engineering and Technology consulting with 37,000 engineers and scientists located in more than 30 countries throughout the world. It serves customers in a range of industries and has a depth and breadth of experience and expertise across life sciences, software development and artificial intelligence. AIXIAL Group, an ALTEN company, is a CRO renowned for its flexible and functional resourcing.
Card image cap
At encapsia, we are pleased to be working with a like-minded partner in endpoint. With both organizations focused on simplifying the user experience and management of complex trials through technology, it was a natural step to integrate our two state-of-the-art technology systems to drive innovation and generate significant efficiencies in the clinical trial space. With encapsia, site users no longer need to use a separate IRT system – they do all their work in encapsia.
Card image cap
Each year we eagerly await the kick-off to the conference season with Arena’s Outsourcing in Clinical Trials (OCT) West Coast event. The conference brings together biotech and pharmaceutical clinical operations, outsourcing and procurement management, while showcasing innovations and technological advancements in the clinical trial space. This year was no exception and although the event was virtual, OCT West Coast managed to gather over 800 clinical trial professionals, looking to meet their peers and share insights into how we can conduct clinical trials of the future.
Card image cap
Running a rare disease study includes many challenges. It’s a more difficult patient population to access which leads to difficulties in patient recruitment, fewer medical experts available, navigation through often complex regulations, as well as potentially complex study designs. This small population makes these studies expensive as you need more sites, maybe across more countries with more time in conduct to achieve your recruitment targets – resulting in costly set-up, management and monitoring of your study.